Loading
10 slides generated from the cancer page, with a quiz from the open benchmark and speaker notes that cite the sources. Arrow keys move between slides; Print gives one slide per page.
Leukaemia means cancer of the blood-forming cells, but the four main types share little beyond the name: acute lymphoblastic and acute myeloid leukaemia are emergencies treated with intensive therapy, while chronic lymphocytic and chronic myeloid leukaemia are slow diseases controlled for years with pills. Each has its own page.
Leukaemias arise when a blood stem cell or its progeny acquires mutations that block maturation and drive proliferation, flooding the marrow and blood with abnormal cells. They are classified by speed (acute or chronic) and lineage (lymphoid or myeloid). Acute lymphoblastic leukaemia is the commonest childhood cancer and is cured in about 90 percent of children; acute myeloid leukaemia is mainly a disease of older adults treated with intensive chemotherapy, venetoclax combinations and transplant; chronic lymphocytic leukaemia is often watched for years and then controlled with BTK and BCL2 inhibitors; chronic myeloid leukaemia became the model of targeted therapy with imatinib. Rarer forms include hairy cell leukaemia and chronic myelomonocytic leukaemia. CAR-T cells and bispecific antibodies are changing the acute leukaemias.
| Setting | Approach | Guideline |
|---|---|---|
| Diagnosis | Blood count and film, bone marrow aspirate and biopsy, flow cytometry, cytogenetics and molecular panel; the subtype then sets the pathway. | not mapped |
| Treatment | By type on the subtype pages: intensive chemotherapy and transplant for acute leukaemias, tyrosine kinase inhibitors for CML, BTK and BCL2 inhibitors for CLL. | not mapped |
| Supportive care | Growth factor support, transfusion, infection prevention and tumour lysis prophylaxis around intensive treatment. | not mapped |